vs
安捷伦科技（A）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是爱德华生命科学的1.1倍（$1.8B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 17.0%，领先6.1%），爱德华生命科学同比增速更快（16.7% vs 7.0%），过去两年爱德华生命科学的营收复合增速更高（9.7% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
A vs EW — 直观对比
营收规模更大
A
是对方的1.1倍
$1.6B
营收增速更快
EW
高出9.7%
7.0%
净利率更高
EW
高出6.1%
17.0%
两年增速更快
EW
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $1.6B |
| 净利润 | $305.0M | $380.7M |
| 毛利率 | 52.6% | 78.0% |
| 营业利润率 | 19.6% | 1.8% |
| 净利率 | 17.0% | 23.1% |
| 营收同比 | 7.0% | 16.7% |
| 净利润同比 | -4.1% | 6.8% |
| 每股收益（稀释后） | $1.07 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEW
| Q1 26 | $1.8B | $1.6B | ||
| Q4 25 | $1.9B | $1.6B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.7B | $1.4B | ||
| Q4 24 | $1.7B | $1.4B | ||
| Q3 24 | $1.6B | $1.4B | ||
| Q2 24 | $1.6B | $1.4B |
净利润AEW
| Q1 26 | $305.0M | $380.7M | ||
| Q4 25 | $434.0M | $91.2M | ||
| Q3 25 | $336.0M | $291.1M | ||
| Q2 25 | $215.0M | $333.2M | ||
| Q1 25 | $318.0M | $358.0M | ||
| Q4 24 | $351.0M | $385.6M | ||
| Q3 24 | $282.0M | $3.1B | ||
| Q2 24 | $308.0M | $366.3M |
毛利率AEW
| Q1 26 | 52.6% | 78.0% | ||
| Q4 25 | 53.2% | 78.1% | ||
| Q3 25 | 51.1% | 77.8% | ||
| Q2 25 | 51.9% | 77.5% | ||
| Q1 25 | 53.5% | 78.7% | ||
| Q4 24 | 53.9% | 78.9% | ||
| Q3 24 | 54.2% | 80.6% | ||
| Q2 24 | 54.4% | 79.9% |
营业利润率AEW
| Q1 26 | 19.6% | 1.8% | ||
| Q4 25 | 23.8% | 9.6% | ||
| Q3 25 | 20.7% | 19.8% | ||
| Q2 25 | 18.0% | 26.8% | ||
| Q1 25 | 22.4% | 27.9% | ||
| Q4 24 | 24.0% | 22.6% | ||
| Q3 24 | 21.1% | 25.9% | ||
| Q2 24 | 23.1% | 26.8% |
净利率AEW
| Q1 26 | 17.0% | 23.1% | ||
| Q4 25 | 23.3% | 5.8% | ||
| Q3 25 | 19.3% | 18.7% | ||
| Q2 25 | 12.9% | 21.7% | ||
| Q1 25 | 18.9% | 25.3% | ||
| Q4 24 | 20.6% | 27.8% | ||
| Q3 24 | 17.9% | 226.7% | ||
| Q2 24 | 19.6% | 26.7% |
每股收益（稀释后）AEW
| Q1 26 | $1.07 | $0.66 | ||
| Q4 25 | $1.53 | $0.16 | ||
| Q3 25 | $1.18 | $0.50 | ||
| Q2 25 | $0.75 | $0.56 | ||
| Q1 25 | $1.11 | $0.61 | ||
| Q4 24 | $1.23 | $0.65 | ||
| Q3 24 | $0.97 | $5.13 | ||
| Q2 24 | $1.05 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | — |
| 总债务越低越好 | $3.0B | — |
| 股东权益账面价值 | $6.9B | — |
| 总资产 | $12.8B | — |
| 负债/权益比越低杠杆越低 | 0.44× | — |
8季度趋势，按日历期对齐
现金及短期投资AEW
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $4.2B | ||
| Q3 25 | $1.5B | $3.8B | ||
| Q2 25 | $1.5B | $4.1B | ||
| Q1 25 | $1.5B | $3.9B | ||
| Q4 24 | $1.3B | $4.0B | ||
| Q3 24 | $1.8B | $4.4B | ||
| Q2 24 | $1.7B | $2.0B |
总债务AEW
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | — | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $3.3B | — | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
股东权益AEW
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $10.3B | ||
| Q3 25 | $6.4B | $10.2B | ||
| Q2 25 | $6.1B | $10.5B | ||
| Q1 25 | $6.0B | $10.1B | ||
| Q4 24 | $5.9B | $10.0B | ||
| Q3 24 | $5.9B | $9.5B | ||
| Q2 24 | $6.2B | $7.4B |
总资产AEW
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $13.7B | ||
| Q3 25 | $12.2B | $13.3B | ||
| Q2 25 | $12.2B | $13.5B | ||
| Q1 25 | $11.9B | $13.0B | ||
| Q4 24 | $11.8B | $13.1B | ||
| Q3 24 | $11.0B | $13.0B | ||
| Q2 24 | $10.9B | $10.1B |
负债/权益比AEW
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.55× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | — |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流AEW
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $450.9M | ||
| Q3 25 | $362.0M | $573.7M | ||
| Q2 25 | $221.0M | $290.2M | ||
| Q1 25 | $431.0M | $280.4M | ||
| Q4 24 | $481.0M | $-127.5M | ||
| Q3 24 | $452.0M | $351.8M | ||
| Q2 24 | $333.0M | $371.5M |
自由现金流AEW
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | $353.5M | ||
| Q3 25 | $259.0M | $516.2M | ||
| Q2 25 | $107.0M | $240.9M | ||
| Q1 25 | $334.0M | $224.4M | ||
| Q4 24 | $388.0M | $-177.3M | ||
| Q3 24 | $360.0M | $299.9M | ||
| Q2 24 | $230.0M | $286.1M |
自由现金流率AEW
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | 22.5% | ||
| Q3 25 | 14.9% | 33.2% | ||
| Q2 25 | 6.4% | 15.7% | ||
| Q1 25 | 19.9% | 15.9% | ||
| Q4 24 | 22.8% | -12.8% | ||
| Q3 24 | 22.8% | 22.1% | ||
| Q2 24 | 14.6% | 20.9% |
资本支出强度AEW
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | 6.2% | ||
| Q3 25 | 5.9% | 3.7% | ||
| Q2 25 | 6.8% | 3.2% | ||
| Q1 25 | 5.8% | 4.0% | ||
| Q4 24 | 5.5% | 3.6% | ||
| Q3 24 | 5.8% | 3.8% | ||
| Q2 24 | 6.5% | 6.2% |
现金转化率AEW
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 4.94× | ||
| Q3 25 | 1.08× | 1.97× | ||
| Q2 25 | 1.03× | 0.87× | ||
| Q1 25 | 1.36× | 0.78× | ||
| Q4 24 | 1.37× | -0.33× | ||
| Q3 24 | 1.60× | 0.11× | ||
| Q2 24 | 1.08× | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
EW
暂无分部数据
